Get the Stockscreener App
7.84
0.51%
0.04
Cogent Biosciences Inc stock is traded at $7.84, with a volume of 2.60M.
It is up +0.51% in the last 24 hours and down -13.66% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
See More
Previous Close:
$7.80
Open:
$7.71
24h Volume:
2.60M
Relative Volume:
1.91
Market Cap:
$866.02M
Revenue:
-
Net Income/Loss:
$-227.05M
P/E Ratio:
-3.5636
EPS:
-2.2
Net Cash Flow:
$-177.93M
1W Performance:
-3.80%
1M Performance:
-13.66%
6M Performance:
-6.22%
1Y Performance:
+51.94%
1-Day Range:
$7.68
$8.06
1-Week Range:
$7.295
$8.555
52-Week Range:
$4.28
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
7.84 | 866.02M | 0 | -227.05M | -177.93M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat
What is HC Wainwright’s Forecast for COGT FY2024 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for COGT Earnings - MarketBeat
Needham Downgrades Cogent Biosciences (COGT) - MSN
Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Receives “Buy” Rating from Needham & Company LLC - Defense World
Cogent Biosciences Announces Updated Clinical Results from Summit, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Given Buy Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences Announces Updated Clinical Results from - GlobeNewswire
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Quantisnow
Cogent Biosciences Announces Positive Updated Data from - GlobeNewswire
Cogent's Bezuclastinib Shows Remarkable 83% Response Rate in Advanced Mastocytosis Trial - StockTitan
(COGT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Fmr LLC Has $89.85 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Reduced by Redmile Group LLC - MarketBeat
Bank of Montreal Can Takes $3.14 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Intech Investment Management LLC Buys Shares of 28,424 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Raises Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
COGT (Cogent Biosciences) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Walleye Capital LLC Acquires Shares of 557,326 Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Eventide Asset Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus PT from Brokerages - Defense World
(COGT) Trading Advice - Stock Traders Daily
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World
What is Leerink Partnrs' Estimate for COGT FY2024 Earnings? - MarketBeat
FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - Defense World
Trend Tracker for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat
Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World
Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat
Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat
FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat
COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Kynam Capital Management, LP Reduces Stake in Cogent Biosciences Inc - GuruFocus.com
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com
Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):